about
Stathmin is dispensable for tumor onset in miceNegative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast CarcinomaFez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.Molecular biology of breast tumors and prognosisRole of T198 modification in the regulation of p27(Kip1) protein stability and functionTargeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical woundingCritical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid glandp27(Kip1)-stathmin interaction influences sarcoma cell migration and invasionThe tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition.A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesisContact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent mannerLoss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells.p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs.Linking inflammation to cell cycle progression.p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability.Stathmin activity influences sarcoma cell shape, motility, and metastatic potential.Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.Meet me in the cytoplasm: A role for p27(Kip1) in the control of H-Ras.Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer.Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway.p27kip1: An all-round tumor suppressor.p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.Stathmin: a protein with many tasks. New biomarker and potential target in cancer.CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma.SUMOylation regulates p27Kip1 stability and localization in response to TGFβ.Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition.p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation.HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.Regulation of Id1 protein expression in mouse embryo fibroblasts by the type 1 insulin-like growth factor receptor.Regulation of Id2 gene expression by the insulin-like growth factor I receptor requires signaling by phosphatidylinositol 3-kinase.Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells.Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.Regulation of thymosin beta10 expression by TSH and other mitogenic signals in the thyroid gland and in cultured thyrocytes.Protein tyrosine phosphatase-eta expression is upregulated by the PKA-dependent and is downregulated by the PKC-dependent pathways in thyroid cells.New light on p27(kip1) in breast cancer.Prostacyclin (PGI2) synthase is a constitutively expressed enzyme in human endothelial cells.Time-tuning cancer therapy.
P50
Q21134036-3A2604BC-5FA4-459D-B120-6778777FD06DQ22242224-C63D333E-E9F9-42AD-8C7A-CD82C1F3071CQ24299543-1DB179C9-01D0-4FFF-BCA1-6B06C1D595E2Q26748546-C98B555B-3704-4CB7-911A-43C37202FEAEQ27349944-5EE7FD2A-EC1C-4176-AD53-3A19F5A5BEDDQ28271265-471C3CD7-443D-44A4-AD14-A91D69C5AEB5Q28583754-2623B680-97F6-461B-B6E4-DCBDFC8E34E1Q28587847-B6310E4B-4D64-428F-A20A-922984E9DD9AQ30490003-5AFF74CD-9779-4A82-AC9C-F8EC6707D83FQ30540674-BB6FDBE5-56A8-48C9-A2D4-C407566BA43DQ33576862-D3F24B62-BAA1-4B88-B8ED-C29C3AABA4AAQ33677415-44B34BA4-A348-4DEE-97F9-82B89838567BQ34434324-05D1888D-887C-4002-96FA-7DADB184BA83Q35768612-D806AFC8-8F57-4E05-BF93-FA039909CAB5Q36300446-7E25FAC9-CA1A-41FE-9D70-0E9690EFE30BQ36631230-05A66836-19E1-460F-B7F3-B7C6613946EDQ36870100-5DCC80AE-813C-42B0-92D9-D322EE149060Q36997861-CE3E20FD-AA4D-4A83-B73D-CC403CB9F832Q37062488-19D2C6D2-E1BA-446E-9272-9648C82A665EQ37266266-8D4B0F7A-2E82-4E9D-B2ED-5D4A135634E9Q37629109-896D04EF-0F85-4119-AB16-09E5E362E84AQ37662085-62697058-ECD4-4DA4-B08A-9BE816D252E9Q37942978-4AFBF073-601C-45FE-AAFA-58988EAF329BQ38639827-1FC2CA71-1282-4D8A-9A91-7B6B596AFF99Q38695855-B9B5BD74-E714-406B-90C8-C7F88C5F2E92Q38754616-5261D654-F845-4E82-856B-B3FBD3AD0749Q38760196-567EDC72-B85D-45BA-9EF0-1A24D115E78CQ38829266-41245706-1419-4625-A2C4-5FC4780E9C77Q38990310-5518AEC3-C98F-4B53-904A-6E92BB2693F8Q39012462-8441C846-F440-428B-877D-E15C36542B36Q40399533-2707A8BB-27A5-4ED4-81D6-5F3DFF6B24D9Q40725748-7AF7F539-4155-419D-9725-252611D0BC29Q40816834-1F6BD064-666F-42FE-B172-9364D9FA91B8Q40851784-C552A7EA-E1C2-4F3C-B7B9-87B15D3EE228Q40912314-03EB8E63-E5BF-4F96-8BD2-402D705AC780Q40948636-2981C9CA-9B9A-41F6-953B-224736E72F4DQ40992652-9DA62EF3-E1D2-496C-89DE-75A7683E7DBEQ42410094-3FC3059C-97B6-4C19-B4E0-F090DAE86D08Q42481606-02C8346D-CA5E-46D2-9793-17C6CAC41B01Q43237751-1680699B-9AE6-45B9-90B4-20BEE2F0E4E0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Barbara Belletti
@ast
Barbara Belletti
@en
Barbara Belletti
@es
Barbara Belletti
@nl
Barbara Belletti
@sl
type
label
Barbara Belletti
@ast
Barbara Belletti
@en
Barbara Belletti
@es
Barbara Belletti
@nl
Barbara Belletti
@sl
prefLabel
Barbara Belletti
@ast
Barbara Belletti
@en
Barbara Belletti
@es
Barbara Belletti
@nl
Barbara Belletti
@sl
P108
P1053
J-2028-2018
P106
P1153
6603835197
P21
P2798
P31
P3829
P496
0000-0003-2249-0285